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Stem cells are cells that can self-renew and differentiate. 
Conceptually, stem cells should be able to generate all func-
tional cells that are required for cell therapy and tissue en-
gineering. Although naturally existing stem cells can be 
harvested from different parts of the body through various 
developmental stages, the technical difficulties in obtaining, 
maintaining and differentiating stem cells hindered the pro-
gress of stem cell application in regenerative medicine. In 
2006, Yamanaka et al. reported a groundbreaking finding 
that somatic cells (for example, fibroblasts) can be “artifi-
cially” induced to a pluripotent state by introduction of four 
transcription factors—Oct4, Sox2, c-Myc and Klf4, and the 
resultant cells were named induced pluripotent stem cells 
(iPSCs) [1]. In 2010, Wernig et al. found that fibroblasts 
can be directly converted to another kind of somatic 
cells—neurons, by using 3 factors—Ascl1, Brn2, and Myt1l, 
suggesting different lineages of cells can be switched given 
sufficient and necessary cues [2]. In agreement with this 
hypothesis, researchers have also successfully converted 
terminally differentiated somatic cells into adult tissue stem 
cells, such as neural stem cells. In light of such paradigm 
shift discoveries that stem cells can now be readily gener-
ated from somatic cells, both public and private funding 
agencies have poured a great deal of investment into this 
area of research, and recent years have seen remarkable 
advances in the basic science and the clinical applications of 
stem cells. In this special topic, we have included five arti-
cles that reviewed recent progress in stem cell biology and 
its applications in regenerative medicine.  
In the article written by Xu DaWei and colleagues [3], 
the roles of the “stemness enzyme”–telomerase in stem cell 
biology were reviewed and discussed. Telomerase plays a 
central part in maintaining telomere length at the end of 
chromosomes. Most somatic cells lack telomerase activity 
and due to the end replication problem, telomeres are 
shortened with each round of cell division. Once the telo-
mere length reaches a critical threshold, growth arrest or 
apoptosis will be triggered. Since one feature of stem cells 
is the ability to self-renew, telomerase is inevitably involved 
in the biology and phenotypes of stem cells. In this review, 
Xu et al. first summarized telomerase activity in normal and 
cancer cells. Telomerase reverse transcriptase (TERT) is the 
rate limiting component for telomerase activity and its ex-
pression is generally repressed in normal cells (except in 
stem cells) but is activated in up to 90% of human malig-
nancies. Then the authors discussed the essential roles of 
telomerase in different types of stem cells—embryonic stem 
(ES) cells, adult stem cells, and iPS cells. In ES cells, TERT 
is highly expressed and telomerase activity is necessary for 
maintaining the immortal and pluripotent phenotypes of ES 
cells. Klf4, -catenin (the effector of Wnt pathway), and 
HIF-1α have been found to interact with TERT as part of 
the regulatory mechanism. In adult stem cells, TERT ex-
pression is relatively lower than that in ES cells, and te-
lomerase activity is not only required for stemness mainte-
nance, but also necessary for the other aspects of stem cells, 
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such as cell mobilization, mitochondria functions, and/or 
epigenetic status. During the reprogramming process to in-
duce iPS cells, telomerase activity is activated and the level 
of activation may determine the extent of reprogramming, 
with the fully reprogrammed cells expressing the highest 
level of telomerase activity. In addition, the authors men-
tioned that controversy still exists with regard to whether 
iPSCs derived from patients carrying mutation of TERT, 
TERC or dyskerin can be used to model the progeria dis-
eases. In the end, the authors discussed the functions of te-
lomerase and alternative telomere-lengthening mechanism 
in cancer stem cells.  
In addition to telomerase, other regulatory mechanisms 
also play critical roles in stem cell biology. Zhao Chen [4], 
in his article, discussed paracrine signaling activities in stem 
cell renewal and neoplastic tumor growth. The interaction 
between epithelial cells and stromal cells is key to embry-
onic development, adult tissue homeostasis and tumorigen-
esis. Hedgehog (Hh) is one of the major morphogens pro-
duced by epithelial cells and can exert effects in an auton-
omous manner on epithelial cells themselves, and in a 
non-autonomous manner on the stromal cells. In turn, stro-
mal cells can respond to Hh signaling and secret soluble 
proteins that influence epithelial cells. Aberrant signaling in 
either the autonomous or the non-autonomous part can lead 
to tumor development. Hh may also directly affect stem 
cells, such as hematopoietic stem cells (HSCs) and the epi-
thelial stem cells in bladder urothelium, although the per-
centages of cells expressing Hh or responding to Hh are not 
clear. Wnt is another family of morphogens that comprise 
19 members. Wnt can be secreted by both the epithelial and 
stromal cells and the mainly responsive cells are epithelial 
stem cells. Proper Wnt signaling is critical for the mainte-
nance of epithelial stem cells and dis-regulation is often 
associated with breast cancer. In some tissues, both Hh and 
Wnt pathways are active. The author continued to discuss 
how these two pathways negatively regulate each other in 
neural tube development and positively regulate each other 
in bladder urothelium. At last, Zhao revealed recent pro-
gress in drug development that target Hh and/or Wnt path-
ways to facilitate tissue regeneration or cancer treatment.  
The crosstalk between major signaling pathways is com-
plex. Wnt pathway not only interacts with Hh pathway, but 
also interacts with Notch pathway. An Songzhu, Li Ling-
Song and colleagues [5] further discussed the intertwined 
network between Notch and Wnt signaling in their article. 
They first summarized the roles of Notch and Wnt pathways 
in normal cells separately, and then pointed out that these 
two pathways interact in different contexts. In hair follicle, 
β-catenin activates the gene encoding Jagges-1, a Notch 
ligand. In stem cell/progenitor cells, β-catenin can bind to 
the cytoplasmic tail of Notch which results in the degrada-
tion of β-catenin, suggesting a negative interaction between 
the two pathways. The authors then presented recent pro-
gress in drug development that target the two pathways in-
dividually or in combination, and illustrated how to take 
advantage of the crosstalk to target an otherwise “undrug-
gable” pathway.  
Stem cells are not only valuable resources for drug de-
velopment, but also hold promise for regenerative medicine. 
Some types of adult stem cells have been successfully ap-
plied in clinics, for example, HSCs to treat leukemia. HSCs 
can give rise to all kinds of cells in blood, including red 
blood cells (RBCs), and may provide a solution to RBC 
shortage in developing countries including China. Pei 
XueTao and colleagues [6] reviewed recent advances in 
RBC generation in their article. They first summarized dif-
ferent protocols for RBC generation from HSCs, and also 
pointed out the limitation in using HSCs given their limited 
ability of self-renewal. The authors further discussed the 
advantages and obstacles in using ES cells and iPS cells for 
RBC production. In addition, they presented current meth-
ods for directing ES/iPS cells towards HSCs which include 
a recent attempt to increase HSC production by adding 
Notch ligand to the culture. In the end, the authors discussed 
the present methods to derive RBCs from ES/iPS cells and 
mentioned that full maturation and efficient enucleation of 
erythroid cells still remain an issue in the field.  
Another type of adult stem cells that have been broadly 
used in clinics is mesenchymal stem cells (MSCs). MSCs 
reside in many tissues, such as bone marrow, adipose tissue, 
umbilical cord blood, dental pulp etc. In addition to the 
basic stem cell features–self-renewal and plasticity, MSCs 
also possess other characteristics, such as the capacity to 
modulate immune signaling, and to produce trophic factors. 
Considering the above beneficial features, MSCs have been 
successfully used in clinical trials to treat osteoarthritis 
(OA). Cao Wei and colleagues [7] reviewed the history and 
current state of MSC therapy for OA. MSCs are the resident 
cells in joint, and their aberrant activity is closely related to 
the onset of pathological changes in OA. MSCs can give 
rise to chondrocytes, adipocytes, and osteocytes; and chon-
drocytes are the major component of cartilage. In contrast to 
traditional therapies that resulted in poor clinical conse-
quences without cartilage repair, intra-articular delivery of 
MSCs has demonstrated feasibility, safety and efficacy. 
After introducing the conventional therapies for OA treat-
ment, the authors compared cell therapies using different 
sources—chondrocytes, adipose-derived MSCs, and bone 
marrow derived MSCs, with preclinical and clinical data. 
Finally, the authors illustrated potential mechanisms under-
lying the efficacy of MSCs, which may involve Wnt, 
BMP-2, Indian Hedgehog, and MAPK signaling pathways.  
Stem cell based regenerative medicine is a very active 
field with great potentials. This collection of five review 
articles does not try to cover the width and depth of this 
dynamic field; rather, it is to highlight some selected pro-
gresses made from mechanistic studies of stem cell biology 
to clinical applications. It is intended to encourage more 
research interests to expand the current scope of regenera-
tive medicine.  
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